Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 11:15:1522558.
doi: 10.3389/fphar.2024.1522558. eCollection 2024.

Safety of ACEI/ARB use in the early (<3 months) post kidney transplant period: a systematic review and meta-analysis

Dahai Fu #  1 , Jin Li #  1 , Guanglan Zeng  1 , Maozhi Tang  2
Affiliations

Safety of ACEI/ARB use in the early (<3 months) post kidney transplant period: a systematic review and meta-analysis

Dahai Fu et al. Front Pharmacol. .

Abstract

Background: Data about the safety of ACEI/ARB use in early (<3 months) posttransplant period are restricted and remain controversial.

Methods: This systematic review and meta-analysis included searches of PubMed, Embase and CENTRAL from inception to 31 November 2023, for studies to compare the safety (transplant outcomes and postoperative complications) of ACEI/ARB with non-ACEI/ARB (other antihypertensive medications) initiation in early post kidney transplant period.

Results: Of 1,247 citations identified, 13 eligible studies involving 1919 patients were enrolled for analyses. In short- or long-term observations, there were no differences on pooled serum creatinine between ACEI/ARB and non-ACEI/ARB groups whether initiated within 1 or 1-3 months posttransplant, however, initiation of ACEI/ARB within the first month posttransplant had an advantage effect on the mean creatinine clearance. Early initiation of ACEI/ARB posttransplant reduced the risks of patient death (RR 0.60, p = 0.009) and graft loss (RR 0.54, p = 0.0002). For postoperative complications, there were no significant differences in acute rejection risk (RR 0.87, p = 0.58), delayed graft function risk (RR 1.00, p = 0.93), hemoglobin level (MD -0.32 mg/Dl, p = 0.46) or urinary protein excretion (MD -0.10 g/24 h, p = 0.16) between two groups. However, the ACEI/ARB group had higher incidence of hyperkalemia (RR 2.43, p = 0.02).

Conclusion: Early initiation of ACEI/ARB within 3 months posttransplant proved to be basically safe and has renal function recovery benefits, however, hyperkalemia needs to be noted.

Keywords: angiotensin converting enzyme inhibitor; angiotensin receptor blocker; kidney transplant; meta-analysis; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow chart for literature search and study selection.
FIGURE 2
FIGURE 2
Forest plots of mean creatinine clearance differences between the ACEI/ARB and non-ACEI/ARB groups in short term observation. ACEI/ARB initiated within the first month posttransplant (2.1.1) and at 1–3 months posttransplant (2.1.2). CI, confidence interval.
FIGURE 3
FIGURE 3
Forest plots of mean serum creatinine differences between the ACEI/ARB and non-ACEI/ARB groups in short term observation. ACEI/ARB initiated within the first month posttransplant (4.1.1) and at 1–3 months posttransplant (4.1.2). CI, confidence interval.
FIGURE 4
FIGURE 4
Forest plots of mean creatinine clearance differences between the ACEI/ARB and non-ACEI/ARB groups in long term observation. ACEI/ARB initiated within the first month posttransplant (3.1.1) and at 1–3 months posttransplant (3.1.2). CI, confidence interval.
FIGURE 5
FIGURE 5
Forest plots of mean serum creatinine differences between the ACEI/ARB and non-ACEI/ARB groups in long term observation. ACEI/ARB initiated within the first month posttransplant (5.1.1) and at 1–3 months posttransplant (5.1.2). CI, confidence interval.
FIGURE 6
FIGURE 6
Forest plots depicting the risk ratios of acute rejection (AR) of early initiation of ACEI/ARB versus non-ACEI/ARB groups. ACEI/ARB initiated within the first month posttransplant (6.1.1) and at 1–3 months posttransplant (6.1.2). CI, confidence interval.
FIGURE 7
FIGURE 7
Forest plots depicting the risk ratios of delayed graft function (DGF) of early initiation of ACEI/ARB versus non-ACEI/ARB groups. CI, confidence interval.
See this image and copyright information in PMC

References

    1. Ahimastos A. A., Natoli A. K., Lawler A., Blombery P. A., Kingwell B. A. (2005). Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertens. 45 (6), 1194–1199. 10.1161/01.HYP.0000168945.44069.aa - DOI - PubMed
    1. Amer H., Griffin M. D. (2014). Modulating kidney transplant interstitial fibrosis and tubular atrophy: is the RAAS an important target? Kidney Int. 85 (2), 240–243. 10.1038/ki.2013.400 - DOI - PubMed
    1. Antlanger M., Domenig O., Kovarik J. J., Kaltenecker C. C., Kopecky C., Poglitsch M., et al. (2017). Molecular remodeling of the renin-angiotensin system after kidney transplantation. J. renin-angiotensin-aldosterone Syst. 18 (2), 1470320317705232. 10.1177/1470320317705232 - DOI - PMC - PubMed
    1. Aziz F., Clark D., Garg N., Mandelbrot D., Djamali A. (2018). Hypertension guidelines: how do they apply to kidney transplant recipients. Transplant. Rev. 32 (4), 225–233. 10.1016/j.trre.2018.06.002 - DOI - PubMed
    1. Chatzikyrkou C., Eichler J., Karch A., Clajus C., Scurt F. G., Ramackers W., et al. (2017). Short- and long-term effects of the use of RAAS blockers immediately after renal transplantation. Blood Press. 26 (1), 30–38. 10.1080/08037051.2016.1182856 - DOI - PubMed

Publication types

LinkOut - more resources